XENE
Xenon Pharmaceuticals Inc
NASDAQ: XENE · HEALTHCARE · BIOTECHNOLOGY
$55.75
+2.24% today
Updated 2026-04-29
Market cap
$5.39B
P/E ratio
—
P/S ratio
718.38x
EPS (TTM)
$-4.36
Dividend yield
—
52W range
$28 – $64
Volume
1.5M
Xenon Pharmaceuticals Inc (XENE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.92M | $14.31M | $27.36M | $28.37M | $15.58M | $1.80M | $311000.00 | $0.00 | $6.83M | $32.17M | $18.44M | $9.43M | $0.00 | $0.00 | $7.50M |
| Revenue growth (YoY) | — | +106.8% | +91.2% | +3.7% | -45.1% | -88.4% | -82.8% | -100.0% | — | +371.0% | -42.7% | -48.8% | -100.0% | — | — |
| Cost of revenue | — | $7.32M | $6.21M | $5.90M | $2.76M | $1.11M | $25.57M | $6.00M | $38.84M | $50.52M | $75.46M | $105.77M | $167.51M | $2.56M | $2.54M |
| Gross profit | $6.92M | $6.99M | $21.15M | $22.47M | $15.58M | $689000.00 | $-25.26M | $-6.00M | $6.83M | $32.17M | $18.44M | $9.43M | $-167.51M | $-2.56M | $4.96M |
| Gross margin | 100.0% | 48.8% | 77.3% | 79.2% | 100.0% | 38.2% | -8122.8% | — | 100.0% | 100.0% | 100.0% | 100.0% | — | — | 66.1% |
| R&D | $12.30M | $10.46M | $12.30M | $11.77M | $15.15M | $19.83M | $25.57M | $23.63M | $38.84M | $50.52M | $75.46M | $105.77M | $167.51M | $210.39M | $300.94M |
| SG&A | $6.73M | $7.01M | $5.34M | $5.50M | $9.79M | $6.79M | $7.31M | $8.38M | $10.80M | $12.94M | $21.97M | $32.81M | $46.54M | $68.90M | $79.63M |
| Operating income | $-12.11M | $-3.15M | $9.71M | $11.11M | $-9.36M | $-24.82M | $-32.58M | $-38.02M | $-42.82M | $-31.30M | $-78.99M | $-129.14M | $-214.05M | $-279.30M | $-373.07M |
| Operating margin | -175.1% | -22.0% | 35.5% | 39.1% | -60.1% | -1376.4% | -10474.3% | — | -627.0% | -97.3% | -428.4% | -1368.9% | — | — | -4974.3% |
| EBITDA | $-10.77M | $-3.42M | $10.42M | $11.84M | $-8.32M | $-23.95M | $-30.05M | $-32.54M | $-39.76M | $-30.66M | $-78.09M | $-127.52M | $-210.51M | $-235.86M | $-342.35M |
| EBITDA margin | -155.7% | -23.9% | 38.1% | 41.7% | -53.4% | -1328.5% | -9664.0% | — | -582.1% | -95.3% | -423.5% | -1351.7% | — | — | -4564.7% |
| EBIT | $-11.90M | $-4.21M | $9.71M | $11.11M | $-9.36M | $-24.82M | $-30.70M | $-33.13M | $-40.18M | $-31.30M | $-78.99M | $-129.14M | $-214.05M | $-238.42M | $-344.89M |
| Interest expense | $91000.00 | $93000.00 | $64000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.39M | $1.43M | $484000.00 | $1.01M | $5.51M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-11.99M | $-4.30M | $12.03M | $13.02M | $-15.75M | $-23.00M | $-30.70M | $-34.50M | $-41.59M | $-28.84M | $-78.88M | $-125.37M | $-182.39M | $-234.33M | $-345.91M |
| Net income growth (YoY) | — | +64.1% | +379.7% | +8.2% | -221.0% | -46.0% | -33.5% | -12.4% | -20.6% | +30.7% | -173.5% | -58.9% | -45.5% | -28.5% | -47.6% |
| Profit margin | -173.3% | -30.1% | 44.0% | 45.9% | -101.1% | -1275.5% | -9872.7% | — | -609.1% | -89.7% | -427.8% | -1328.9% | — | — | -4612.1% |